As an example, for people with the G551D mutation, the orally bioavailable potentiator drug, VX770, shows substantial promise as an inducer of mutant CFTR channel activity, and thus is FDA approved for clinical application in CF patients (Accurso et al., 2010). This evidence concerns the gene CFTR and cystic fibrosis.